Drug Discovery

AI in drug discovery is set to grow 25-30% over five years. Read a concise briefing on drivers, key applications like oncology, major innovations and remaining hurdles.

Merck teams with Mayo Clinic to combine Mayo Clinic Platform data and Merck’s AI virtual cell tools to speed AI-driven drug discovery for IBD, atopic dermatitis and MS.

Major pharma firms are realizing real ROI from AI now — through faster R&D workflows, smarter trials, and commercial and administrative savings rather than headline drug discoveries.

Generative AI is reshaping drug discovery by predicting protein structures, designing antibodies, and making GPCRs targetable. Learn how GenAI shortens timelines and opens new therapies.

Insilico Medicine and Qilu Pharmaceutical launched a strategic collaboration using Chemistry42 and Biology42 to discover cardiometabolic drug candidates. Read a concise analysis of what this deal means for AI adoption in pharma.

LIGAND-AI, a €60M international initiative led by Pfizer and SGC with UCL, will publish large protein-ligand datasets and AI models to speed drug discovery for rare, neurological and cancer targets.

An AI-designed molecule has moved into Phase 1 trials after a high-profile partnership and funding round. What this milestone means for drug timelines, investors, and patients.

Explore how AI shortens drug discovery timelines, improves target selection and compound design, and what this means for new treatments and patient care.

How AI is accelerating RNA drug discovery with data-driven models, deep learning, and interactive workflows, cutting costs and timelines for pharma and investors.

PreciseDx joins industry leaders at the NYC Leadership Summit to discuss AI-driven drug discovery, PreciseBreast, and the balance between innovation and regulation.